Francis C Lee

7169568, Jan 30, 2007

Oct 19, 2001

09/982095

Moses V. Chao - New York NY, US
Francis S. Lee - San Francisco CA, US

New York University - New York NY

G01N 33/567

435 721

The present invention is directed to a method for screening and identifying molecules that transactivate a neurotrophin receptor and mediate neuronal cell survival in the absence of neurotrophins which uses one or a combination of three different assays. The assays involve detecting the phosphorylation of a neurotrophin receptor, detecting the phosphorylation of phosphotidylinositol 3′-kinase or Akt enzyme, and assessing neuronal cell survival in the absence of neurotrophins.

20050010305, Jan 13, 2005

Jan 28, 2004

10/766084

Francis Lee - Fort Lee NJ, US

A61F002/28

623023510

A bone graft composite comprising a bisphosphonate is provided which is suitable for treating bone destruction. The bisphosphonate provides bone graft protection.

20090319044, Dec 24, 2009

Jan 31, 2007

12/223503

Francis Young-In Lee - Fort Lee NJ, US

A61F 2/28
A61L 27/54
A61P 19/00
A61B 17/58

623 1611, 424423, 606 86 R

The present invention provides methods of improving the incorporation of an implantable device into a bone of a host in need thereof. More particularly, the methods of the present invention include implanting the device into the bone of a host, wherein the device is at least partially made of a non-metallic material. Disposed on at least one surface of the device is an amount of hydroxyapatite and bisphosphonate, which in combination, are effective to reduce osteolysis and improve incorporation of the implant into the host bone compared to an implant without the hydroxyapatite and/or bisphosphonate. The present invention also provides methods for making such implants, as well as, the implants themselves.

20100240763, Sep 23, 2010

Jan 19, 2007

12/223053

Francis S. Lee - New York NY, US
Barbara L. Hempstead - New York NY, US
Kevin G. Bath - New York NY, US

C12Q 1/68
A61K 31/138
A61P 25/24

514651, 435 6

The invention provides a method for determining whether a patient suffering from a condition that is susceptible to treatment with a compound that activates the brain serotonin system is resistant to treatment with the compound. The method comprises observing whether the genome of the patient contains at least one copy of the BDNF allele containing a genetic alteration, and correlating the presence of the allele containing the genetic alteration with patients who are resistant to treatment with the compound. In another embodiment, the method comprises observing whether the patient expresses a BDNF protein containing an amino acid alteration, and correlating the expression of the BDNF protein containing the amino acid alteration with patients who are resistant to treatment with the compound.

20110207827, Aug 25, 2011

Jun 16, 2009

12/999581

Francis S. Lee - New York NY, US
Barbara Hempstead - New York NY, US
James Kocsis - Roxbury CT, US
Kevin Bath - New York NY, US

CORNELL UNIVERSITY - Ithaca NY

A61K 31/135
C12Q 1/68
A61P 25/24

514651, 435 613, 435 611

The invention relates to a method for determining whether a patient suffering from a condition that is susceptible to treatment with a compound that activates the brain serotonin system is susceptible or resistant to treatment with the compound. The method includes establishing whether the patient is a pre-adult, a transition age patient, or an adult and observing whether the genome of the patient contains at least one copy of a BDNF allele having a genetic alteration. The method further includes correlating the presence of the allele containing the genetic alteration with susceptibility or resistance of the patient to the treatment with the compound, wherein a pre-adult patient containing the genetic alteration is correlated as being susceptible to the treatment; a transition age patient containing the genetic alteration is correlated as being susceptible or resistant to the treatment; and an adult patient containing the genetic alteration is correlated as being resistant to the treatment.

20120322068, Dec 20, 2012

Jan 14, 2011

13/522079

Francis S. Lee - New York NY, US
Bj Casey - New York NY, US

CORNELL UNIVERSITY - Ithaca NY

C12Q 1/68
A61B 5/055

435 611, 600411

The present invention is for methods for identifying a human having an increased risk for anxiety disorders. The method involves genotyping the human for a specific brain-derived neurotrophic factor (BDNF) single nucleotide polymorphism (SNP), and/or administering a fear conditioning procedure while measuring fear, and administering an extinction procedure while measuring fear. The method can also involve comparing/MRI images of the amygdala of the human acquired during conditioning and extinction and determining if the human is unresponsive to extinction therapy by noting heightened and non-declining activity in the amygdala during extinction.

20220378924, Dec 1, 2022

Jul 18, 2022

17/867025

- Monmouth Junction NJ, US
Aranapakam M. VENKATESAN - Rego Park NY, US
Feng CHEN - Princeton NJ, US
Fei WU - Plainsboro NJ, US
Melik Ziya TÜRKER - Princeton NJ, US
Gregory Paul ADAMS - Hatboro PA, US
Francis Y.F. LEE - Yardley PA, US

A61K 47/55
A61K 47/69
A61K 47/60
A61K 47/54
A61P 35/00

The disclosure relates to nanoparticle drug conjugates (NDC) that comprise ultrasmall nanoparticles, folate receptor (FR) targeting ligands, and linker-drug conjugates, and methods of making and using them to treat cancer.

20210163445, Jun 3, 2021

Dec 10, 2018

16/770697

- North Brunswick NJ, US
Zhiqiang Yang - Westfield NJ, US
Francis Lee - Yardley PA, US
John Qiang Tan - North Brunswick NJ, US

C07D 401/12
C07D 215/22
C07D 487/04
C07D 487/08
C07D 403/12

The present disclosure describes carbamate and urea compounds as novel multikinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such multikinase inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders associated with kinases are also described.